Objective-Cardiovascular diseases and depression are the leading causes of disability in Western countries. Clinical data on potential cardiovascular effects of serotonin reuptake inhibitors (SSRIs), the most commonly used antidepressant drugs, are controversial. In addition to blocking serotonin reuptake transporter in the brain, SSRIs deplete the major peripheral serotonin (5-hydroxytryptamine [5-HT]) storage by inhibiting serotonin reuptake transporter-mediated uptake in platelets. In this study, we aimed to investigate the effect of chronic SSRI intake on the development of atherosclerosis. Approach and Results-Treatment of apolipoprotein E-deficient mice with the SSRI fluoxetine for 2, 4, or 16 weeks increased atherosclerotic lesion formation, with most pronounced effect during early plaque development. Intravital microscopy of carotid arteries revealed enhanced myeloid cell adhesion on fluoxetine treatment. Mechanistically, we found that fluoxetine augmented vascular permeability and increased chemokine-induced integrin-binding activity of circulating leukocytes. In vitro stimulation of murine blood demonstrated that fluoxetine, but not 5-HT, could directly promote β1 and β2 integrin activation provided C-C motif chemokine ligand 5 was also present. Similar effects were observed with the SSRI escitalopram. Enhanced C-C motif chemokine ligand 5-induced integrin activation by fluoxetine was also confirmed in a human neutrophil-like cell line. In contrast to the proatherogenic properties of fluoxetine, pharmacological inhibition of the peripheral 5-HT synthesizing enzyme tryptophan hydroxylase 1 did not promote atherosclerosis, suggesting that the proatherogenic effect of fluoxetine occurs independent of peripheral 5-HT depletion. Conclusions-SSRI intake may promote atherosclerosis and therefore potentially increase the risk for acute cardiovascular events by a mechanism that is independent of 5-HT depletion. Visual Overview-An online visual overview is available for this article.
S erotonin or 5-hydroxytryptamine (5-HT) is best known for its role as a neurotransmitter in the central nervous system, where it regulates various functions, such as mood, behavior, and appetite. Impaired 5-HT signaling is associated with psychiatric disorders, such as depression. However, the vast majority (≈95%) of 5-HT can be found in the periphery where it is produced by tryptophan hydroxylase 1 (TPH1) mainly in enterochromaffin cells in the gastrointestinal tract. [1] [2] [3] On synthesis, 5-HT is secreted into the circulation, where it is directly taken up by platelets via the serotonin reuptake transporter (SERT) and stored in their dense granules. After activation, platelets release their granule content, including 5-HT. 4 It has been shown that peripheral 5-HT is involved in a variety of different physiological processes, including regulation of vascular tone, 5 vascular permeability, 6 intestinal motility, 7 platelet aggregation, and degranulation. 8 The 5-HT signaling is mediated by various receptors (5-HTR1 to 5-HTR7) and terminated on the part of the receptor ligand 5-HT by reuptake via SERT into platelets. 4 SERT is also expressed on neurons where it represents the primary target of the first-line antidepressants called selective serotonin reuptake inhibitors (SSRIs). 1 Because platelets are not able to synthesize 5-HT themselves, chronic intake of SSRIs results in a depletion of platelet 5-HT and thereby loss of its main peripheral storage. 9 According to the World Health Organization, >300 million people worldwide are experiencing depression. 10 Consequently, SSRIs, such as fluoxetine , are among the most common drugs being prescribed. 11, 12 Clinical studies investigating potential cardiovascular effects of SSRIs and the risk for developing an acute cardiovascular event are controversial. On the one hand, there are published data showing no increased or even lower cardiovascular risk for patients taking SSRIs. [13] [14] [15] [16] On the other hand, different studies report opposing findings, suggesting a link between SSRI intake and a higher risk for developing cardiovascular events. [17] [18] [19] Interpreting these conflicting results becomes even more complex when considering the fact that depression per se is a well-established cardiovascular risk factor. 20 Because results from existing clinical studies are inconclusive to clarify a possible association between SSRI intake and cardiovascular diseases, other than observational studies are needed. We, therefore, aimed to shed light on this topic by investigating the effect of chronic SSRI intake on atherosclerosis onset and progression in a mouse model.
Materials and Methods
Please see the Major Resources Table in the online-only Data Supplement for additional experimental details.
Mice
Male apolipoprotein E-deficient (ApoE −/− ) mice on C57Bl/6 background aged 6 to 8 weeks were either fed a high-fat diet (HFD) only (Western diet; ssniff) for 2, 4, or 16 weeks, respectively (control group), or treated in parallel with fluoxetine (160 mg/L; Prozac, Lilly) via the drinking water. 6 In a selective experimental condition, fluoxetine treatment was initiated 2 weeks before starting HFD feeding and then continued for another 2 weeks in parallel to HFD. Wild-type C57Bl/6 mice were treated with fluoxetine for 2 weeks. In other experiments, ApoE −/− mice received daily intraperitoneal injections of TPH1 inhibitor LP533401 (25 mg/kg, Dalton Pharma Services) dissolved in dimethyl sulfoxide and diluted in aqua ad injectabilia or equal volume of vehicle in parallel to 2 or 4 weeks HFD feeding. 21 At the end point, mice were anesthetized with ketamine/xylazine, and blood was obtained via cardiac puncture unless otherwise noted. Heart, aorta, spleen, and femurs were harvested after PBS perfusion. All animal experiments were approved by the local Ethics committee (District Government of Upper Bavaria; License Number: 55.2-1-54-2532-111-13) and conducted in accordance with the institutional and national guidelines.
Intravital Microscopy
Intravital microscopy was used to analyze leukocyte-endothelial interactions along the carotid artery of ApoE −/− mice after 4 weeks HFD±fluoxetine treatment as described previously. 22 In brief, antibodies against Ly6G-phycoerythrin (PE) and CD11b-650NC were injected to label myeloid cells and allowed to circulate for 10 minutes to label peripheral myeloid cells. Intravital microscopy of the surgically exposed left external carotid artery was performed using a BX51 (Olympus) microscope. For image acquisition and analysis, Olympus Excellence software was used. Rolling flux was measured as the number of cells passing a reference line perpendicular to blood flow within 30 seconds. When no rolling was observed for at least 30 seconds, cells were defined to be adherent.
Quantification of 5-HT and Chemokines in Serum and Plasma
Murine blood was collected retro-orbitally. For serum, blood was collected in Serum Gel Z tubes and allowed to clot for 30 minutes at room temperature (RT). Plasma was obtained from EDTAanticoagulated whole blood. To avoid platelet activation, 1 µmol/L prostaglandin E1 (Cayman) was added. The 5-HT was measured with Serotonin Fast Track ELISA (Labordiagnostika Nord). CXC motif chemokine ligand 4 and chemokines C-C motif chemokine ligand 5 (CCL5) were analyzed in serum and in supernatant of activated platelets using DuoSet ELISA kits (R&D systems).
Histology and Immunohistochemistry
Hearts were isolated after perfusion with PBS and frozen in Tissuetek (Sakura Finetek). Aortic roots were cut in 5-μm thick serial cryosections. For the quantification of lesion size, sections were stained with Oil-Red O. Plaque macrophage content was quantified using an antibody against Mac-2 visualized with the alkaline phosphatase enzyme detection system using the VECTASTAIN ABC-AP staining kit (Vector Laboratories). Total collagen was quantified via Sirius red staining. For analysis, the Leica Application Suite LAS V4.3 software was used.
Cholesterol Measurements
Total plasma cholesterol concentrations were quantified using a colorimetric assay (CHOD-PAP, Roche) according to the manufacturer's protocol. The neutral lipid content in blood leukocytes was determined with Amplex Red Cholesterol Assay Kit (Invitrogen) 23 and presented as ratio of esterified to total cholesterol. After erythrocyte lysis in ammonium chloride potassium lysis buffer, cells were resuspended in cold 1× buffer and incubated on ice for 1 hour. Samples were heated at 60°C for 30 minutes to destroy endogenous esterases, followed by shaking for 30 minutes at RT. To measure total and esterified cholesterol, the assay was performed according to the manufacturer's protocol with and without esterase.
Assessment of Blood Cell Counts
Blood leukocyte, platelet counts, and mean platelet volume were measured from EDTA-anticoagulated whole blood with a hematology analyzer (scil Vet ABC Hematology Analyzer).
Flow Cytometry
To obtain single cell suspensions, spleens were meshed through a 70-µm cell strainer, and femurs were centrifuged for 2 minutes at 9000g. Erythrocytes were lysed using ammonium chloride potassium buffer. After Fc blocking with CD16/CD32 antibody for 5 minutes on RT, cells were stained for 30 minutes in the dark with an antibody mix for neutrophils and monocytes (CD45. 
Flow Cytometric Analysis of PlateletLeukocyte Aggregates
Blood was carefully obtained via cardiac puncture using a 26G needle and a syringe containing 100 µL acid citrate dextrose buffer. A total of 150 µL blood was incubated with 1 mL red blood cell Lysis/ Fixation Solution (BioLegend) for 15 minutes at RT. After washing and Fc blocking, cells were stained (CD45.2-fluorescein isothiocyanate, CD11b-PerCP, Ly6G-ACP/Cy7, CD115-PE, CD41-APC) for 20 minutes at RT. Platelet-leukocyte aggregates were measured by flow cytometry with a low flow rate and identified as leukocytes, which were also positive for platelet marker CD41.
In Vivo Permeability Assay
ApoE −/− mice fed an HFD for 2 weeks±fluoxetine were injected intravenously with 0.5% Evans blue solution in 0.9% saline (40 mg/kg, Sigma Aldrich). After 30 minutes, mice were anesthetized and perfused with PBS. Spleen, heart, and kidney were collected, air dried, and weighted. To extract Evans blue, organs were incubated with 450 µL formamide at 56°C for 24 hours. 25 The optical density of the extracted dye was measured at 620 nm. Vascular leakage was determined as ng of Evans blue extravasated per mg tissue using a standard curve. Endothelial permeability in aortic arches was assessed by confocal laser scanning microscopy. Aortic arches were dissected, fixed in 4% paraformaldehyde solution, mounted on microscopy slides after imaging with a Leica TCSII SP8 3X (Leica Microsystems) equipped with a ×20 multi-immersion objective (numeric aperture, 0.75), and a motorized stage. The whole sample was acquired as a tilescan of 775×775×120 to 200 μm xyz stacks. Evans blue was excited with a continuous white-light laser tuned at 580 nm, and the emitted fluorescence was collected in the 660 to 720 nm range with a hybrid diode detector. Tilescan volumes were reconstructed and processed using Imaris 8.4 (Bitplane, Switzerland). Z sectioning allowed to remove the external adventitial layer, strongly autofluorescent, and to expose the underneath Evans blue-positive signal of the endothelium, which was quantified as a volume after application of an ad hoc mask.
Murine Integrin Activation Assay
Murine blood was drawn from wild-type or ApoE −/− mice as indicated in the respective experiment. Erythrocytes were lysed, and leukocytes were resuspended in Hanks' balanced salt solution with Ca 2+ /Mg 2+ and 0.5% BSA. In the presence of recombinant ICAM-1/Fc chimera or VCAM-1/Fc chimera (2.5 μg/mL; R&D Systems), which were prelabeled with anti-human IgG Fc-PE, cells were incubated with 5-HT (1 µmol/L), fluoxetine (1 µmol/L), or escitalopram (0.1 µmol/L, Sigma Aldrich) for 15 minutes at 37°C after stimulation with CCL5 (5 μg/mL, Peprotech) for 5 minutes. 26 Cells were stained, and neutrophils were identified as CD45 
Assessment of High-Affinity β2 Integrin Conformation on HL 60 Cells
The human promyelocytic leukemia cell line HL 60 was cultured in RPMI (Roswell Park Memorial Institute)-1640 medium, containing 10% fetal calf serum and 1% penicillin/streptomycin. For differentiation into neutrophil-like cells, 1×10
6 cells were cultured in 10 mL RPMI-1640 (10% fetal calf serum, 1% penicillin/streptomycin) medium supplemented with 1.3% dimethylsulfoxyd for 6 days. 27, 28 To analyze the high-affinity conformation of β2 integrins on HL 60 cells, an anti-CD11/CD18 antibody (mAb24) 29 and the secondary Alexa Fluor 488-conjugated (Fab')2 antibody were used as previously described. 
Isolation and In Vitro Stimulation of Platelets
Blood was taken by heart puncture using a 26G needle and a syringe containing 100 µL acid citrate dextrose buffer into a citrate tube. Platelet-rich plasma was obtained by centrifugation at 100g for 10 minutes at RT without break. After washing, platelets were obtained via centrifugation at 2600g for 5 minutes at RT and resuspended in 300 µL prewarmed tyrode buffer. The 2×10 8 platelets were activated by stimulation with 0.5 U/mL thrombin for 20 minutes at 37°C. After pelleting, supernatants were collected for ELISA. Platelet activation was determined by CD62P-PE staining after flow cytometry analysis of geometric mean fluorescence intensity.
In Vitro Stimulation of Murine Endothelial Cells
Murine endothelial cells SVEC4-10 were grown to confluence in RPMI-1640 (10% fetal calf serum, 1% penicillin/streptomycin). Cells were pretreated with fluoxetine or 5-HT (1 µmol/L) in serumfree medium for 15 minutes, after stimulation with tumor necrosis factor-α (10 ng/mL; BioLegend) for 6 hours. After washing, cells were stained with antibodies against ICAM-1-APC and VCAM-1-PerCP/Cy5.5. Protein expression levels were measured by flow cytometry and calculated via mean fluorescence intensity.
Isolation of Monocytes and Neutrophils From Bone Marrow
Bone marrow cells were obtained from femurs by centrifugation. Cells of 3 mice were pooled, and neutrophils or monocytes were isolated by negative selection using Neutrophil or Monocyte Isolation Kit (Miltenyi Biotec). The obtained purity of neutrophils and monocytes was 98% and 85%, respectively.
Quantitative Real-Time Polymerase Chain Reaction
Aortas were homogenized and lysed using the TissueLyser LT (Qiagen) for extraction of total RNA (peqGold Trifast and Total RNA kit, Peqlab). After reverse transcription (PrimeScript RT reagent kit, Clontech), real-time polymerase chain reaction was performed with the 7900HT Sequence Detection System (Applied Biosystems) using the KAPA PROBE FAST Universal qPCR kit (Peqlab). Primers and probes were purchased from Life Technologies or self-designed. Target gene expression was normalized to HPRT (hypoxanthineguanine phosphoribosyltransferase) and presented as relative transcript level (2
−ΔΔCt
). For comparison of relative 5-HTR and SERT expression between murine monocytes and neutrophils, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as additional housekeeping control for normalization.
Generation of 5-HTR2a-Overexpressing HEK293 Cells
The plasmid carrying the human coding sequence for the 5-HT receptor 2a (5-HTR2a) flanked by BamHI (5′) and XhoI (3′) restriction sites was purchased from cDNA Resource Center. The coding region was cloned into the pcDNA5/FRT/TO expression vector (Invitrogen), N-terminally fused to the coding sequence for yellow fluorescent protein. For stable and inducible expression of the construct, Flp-In T-Rex-293 (HEK [human embryonic kidney] 293) cells, cultured in DMEM (10% fetal calf serum, 1% penicillin/streptomycin), were transfected using EcoTransfect reagent (OZ Biosciences), and clones were selected with hygromycin (0.25 mg/mL; Invivogen). Receptor expression in isolated clones was induced by tetracycline (0.5 µg/mL; Sigma Aldrich) 2 days before the experiment.
Calcium Assay
Intracellular calcium concentrations were measured using FLPR Calcium 5 Assay Kit (Molecular Devices). Briefly, stably transfected cells were seeded with medium containing tetracycline in 96 wells, pretreated with 0.01% poly-d-lysine (Sigma Aldrich). After incubation for 48 hours, cells were loaded with FLIPR Calcium 5 dye for 1 hour at 37°C. Fluorescence of the calcium sensitive dye (excitation: 485 nm, emission 525 nm) was measured at 37°C before and after addition of fluoxetine or 5-HT with an Infinite F200 PRO microplate reader (Tecan Trading AG). Relative light units were normalized to basal levels and presented as x-fold over basal level.
Statistical Analysis
All data are shown as mean±SEM. Statistical analyses were performed using GraphPad Prism 7 software. To test for Gaussian distribution, D'Agostino Pearson omnibus or Shapiro-Wilk normality test was applied. After comparing variances via F test, Student t test was used for normally distributed data with equal variances. If variances were significantly different, Welch t test was applied. Mann-Whitney U test was performed if normality test failed. For highly screwed data sets, log transformation was applied before statistical calculations (only applied for data shown in Figure IIIB in the online-only Data Supplement). For multiple comparisons, after testing for normal distribution, either 1-way ANOVA followed by Bonferroni post hoc test or Kruskal-Wallis test followed by Dunn post hoc test was applied. For 2 independent factors, 2-way ANOVA followed by Bonferroni post hoc test was performed. Outliers were determined by Tukey method. A P<0.05 was considered statistical significant.
Results

Fluoxetine Treatment Depletes Platelet 5-HT Without Affecting Free Circulating Plasma Levels
To validate the efficiency of chronic fluoxetine treatment on peripheral 5-HT depletion in ApoE −/− mice, we first performed a time course experiment. It has been reported that chronic oral intake of 18 mg/kg per day fluoxetine in mice resulted in fluoxetine plasma concentrations equivalent to those measured in patients receiving 20 to 80 mg/d fluoxetine. 31 Therefore, we decided to administrate the dose of 160 mg/L fluoxetine via the drinking water, 6 which approximately corresponds to 18 mg/ kg per days. Plasma levels of 5-HT reflecting free circulating 5-HT not stored by platelets were generally low and not significantly changed by fluoxetine ( Figure 1A ). As expected, fluoxetine induced a significant decrease of serum 5-HT, which was already detectable after 7 days of treatment ( Figure 1B ). This indicates that SERT inhibition specifically inhibited 5-HT storage in platelets. After 14 days, a depletion efficiency of 88% was achieved ( Figure 1C) . Furthermore, we observed that HFD feeding progressively decreased 5-HT serum levels in ApoE −/− mice, possibly because of enhanced platelet activation stage and consequently reduced storage ( Figure 1D ).
Fluoxetine Treatment Enhances Atherosclerotic Plaque Formation
To investigate the influence of fluoxetine on the onset and progression of atherosclerosis, ApoE −/− mice received fluoxetine treatment in parallel to HFD feeding for 2, 4, or 16 weeks, respectively. We did not observe any effect of fluoxetine on body weight or plasma total cholesterol levels at any of the investigated time points (Tables I and II in the online-only Data  Supplement) . In addition, fluoxetine did not affect the neutral lipid content in circulating leukocytes as evidenced by similar ratios of esterified to total cholesterol levels in treated and control mice ( Figure IA in the online-only Data Supplement). Moreover, no changes in protein levels of cholesterol transporters were detectable on blood nonclassical monocytes on fluoxetine treatment ( Figure IB in the online-only Data Supplement). Atherosclerotic lesion size in aortic roots was increased at all stages of atherosclerosis compared with untreated controls (Figure 2 ). Acute fluoxetine treatment was previously shown to transiently elevate plasma 5-HT concentrations, as a consequence of blocked 5-HT uptake by platelets. 32 To exclude the possibility that the proatherogenic effects might be solely caused by a short-term peak of 5-HT plasma levels during onset of fluoxetine treatment, we also performed a pretreatment experiment, starting fluoxetine administration before HFD onset. However, the resulting plaque phenotype was similar to the one observed in our initial experimental setup ( Figure II in the online-only Data Supplement).
Because the proatherogenic effect was most pronounced in the early phase of atherogenesis and this stage of plaque formation mainly involves myeloid cell recruitment, we assessed macrophage plaque content by immunohistochemistry after 4 weeks HFD. We found significantly higher amounts 
Fluoxetine Treatment Transiently Reduces Circulating Leukocyte and Platelet Counts Without Affecting Myelopoiesis
During atherogenesis, monocytes and neutrophils are mobilized from the bone marrow into the blood and recruited into the arterial wall. We asked whether higher intimal macrophage content might be a consequence of enhanced monocyte infiltration, possibly because of changes in endothelial activation or myelopoiesis and mobilization from the bone marrow. Surprisingly, blood count analysis during the initial time course experiment revealed a marked decrease in circulating granulocyte counts after 14 days of fluoxetine treatment ( Figure 
Fluoxetine Treatment Enhances In Vivo Adhesion of Myeloid Cells to Carotid Arteries
To validate this hypothesis, we performed in vivo imaging of myeloid cell recruitment to the carotid artery bifurcation using intravital fluorescence microscopy. After 4 weeks of HFD and fluoxetine treatment, we administered fluorescently labeled antibodies to identify circulating myeloid cells (CD11b + ) and neutrophils (Ly6G + ). Although rolling on the endothelium was not affected, the number of adhering myeloid cells to the vessel wall was 2-fold higher in fluoxetine-treated mice compared with untreated control mice (Figure 3) . The effect was even more striking when selectively quantifying neutrophil adhesion, which was 3.5-fold higher. Because selectin-dependent leukocyte-endothelium interactions were not altered, we speculated that fluoxetine treatment might affect integrinbinding affinity, which is relevant for leukocyte adhesion.
Fluoxetine Treatment Does Not Affect Platelet Characteristics
Platelets were previously described to aggravate atherosclerosis by forming platelet-leukocyte aggregates and thereby releasing the platelet-derived CCL5 and CXC motif chemokine ligand 4. 33 We speculated that the depletion of 5-HT storage might affect these proatherogenic platelet properties. However, no differences in circulating platelet-leukocyte aggregates between fluoxetine-treated and control mice were detectable ( Figure VII 
Fluoxetine Treatment Increases Vascular Permeability
In atherosclerosis, the barrier function of the endothelium is disrupted leading to increased vascular permeability. This facilitates transendothelial migration of leukocytes to the arterial intima. 34 Because platelet 5-HT was reported to be involved in the regulation of vascular integrity, 6 we investigated the effect of fluoxetine on vessel leakage using an in vivo permeability assay. 
Fluoxetine Treatment Does Not Increase Endothelial Adhesion Molecule Expression
Enhanced myeloid cell adhesion on endothelium might be promoted by increased expression of adhesion molecules on arterial endothelium or circulating leukocytes. To clarify the potential effects on endothelial cells and aortic inflammatory cytokines, we measured aortic mRNA expression of adhesion molecules, chemokines, as well as chemokine receptors after 4 weeks of fluoxetine treatment and HFD (Figure X in the online-only Data Supplement). We did not detect any changes that would support augmented leukocyte recruitment. Given that differences in surface expression levels might be because 
Fluoxetine Treatment Enhances CCL5-Induced Integrin Activation
We subsequently focused on circulating leukocytes. Measurement of adhesion molecules on blood neutrophils, more precisely selectins and integrins, did not reveal differences between fluoxetine-treated and control mice ( Figure 4B ). Because integrin-mediated binding depends on conformational changes rather than regulation of surface expression, we analyzed β1 and β2 integrin-binding activity to their natural ligands ICAM-1 and VCAM-1 in response to leukocyte stimulation with CCL5 ( Figure 4C and 4D) . After 2 weeks of in vivo fluoxetine treatment, circulating neutrophils and classical monocytes exhibited an increased CCL5-induced binding affinity to ICAM-1 and VCAM-1. To better clarify whether enhanced integrin activation in mice chronically treated with fluoxetine is a consequence of platelet 5-HT depletion or possibly a direct effect of fluoxetine on blood leukocytes, we performed additional in vitro experiments. In vitro stimulation of whole blood obtained from wild-type mice revealed increased CCL5-induced integrin activation after fluoxetine but not 5-HT treatment ( Figure 5A ). This finding suggests a direct effect of fluoxetine on leukocytes independent of peripheral 5-HT depletion. Of note, enhanced integrin-mediated binding was only observed on chemokine costimulation, whereas fluoxetine alone did not promote binding to VCAM-1 or ICAM-1 ( Figure 5B-5C ). In line with these findings measuring integrin, high-affinity conformation with the mAb24 reporter antibody revealed upregulation of β2 integrin activation in the presence of fluoxetine on CCL5-stimulated human HL 60 cells compared with CCL5 treatment alone. Similar to murine leukocytes, treatment with 5-HT did not affect CCL5-induced integrin activation and fluoxetine stimulation in the absence of CCL5 did not induce β2 integrin activation in the human system ( Figure 5D ). This implies that the fluoxetine-mediated and 5-HT-independent effect on integrin activation is also relevant for human cells and CCL5 dependent. To examine whether the increase of integrin activity is solely mediated by fluoxetine or possibly also triggered by other SSRIs, we performed additional integrin activity assays using escitalopram. Escitalopram is the newest clinically available SSRI, showing advantages in terms of efficacy and tolerability compared with other SSRIs. Compared with other SSRIs, which block 5-HT transport of SERT only by orthosterically binding in the central cavity, escitalopram additionally binds to an allosteric site. 35, 36 Remarkably, escitalopram also strongly increased VCAM-1 binding on monocytes and neutrophils in the presence of CCL5 while According to previously published data, fluoxetine may not only bind to SERT but also to several 5-HTRs. 37 We measured mRNA levels of SERT and several 5-HTRs in isolated murine monocytes and neutrophils ( Figure XIII in the onlineonly Data Supplement). In addition to SERT, we were able to detect 5-HTR1b and 5-HTR2a mRNA expression in monocytes and to a lower extend in neutrophils. Affinity assays reported binding of fluoxetine to 5-HTR2a with much higher affinity than to 5-HTR1b. 37 Because 5-HTR2a is a G protein-coupled receptor coupled to G q 38 and intracellular Ca 2+ is essential for integrin activation, [39] [40] [41] we tested the possibility that fluoxetine might generate an increase of Ca 
Pharmacological TPH1 Inhibition Does Not Promote Atherogenesis
To strengthen our hypothesis that the proatherogenic effect of fluoxetine treatment was not a consequence of peripheral 5-HT depletion, we used an additional approach for in vivo 5-HT depletion using a pharmacological inhibitor of the peripheral 5-HT-synthesizing enzyme TPH1. Daily administration of the TPH1 inhibitor LP-533401 for 2 weeks in parallel to HFD resulted in efficient depletion of peripheral 5-HT ( Figure 6A ). Of note, TPH1 inhibition did not influence circulating leukocyte or platelet counts ( Figure 6B) . Interestingly, chronic treatment with TPH1 inhibitor had an opposing effect on early plaque formation compared with 
Discussion
Cardiovascular disease and depression are the most important health burdens in high-income countries, and there is increasing evidence for a causal relationship between both diseases. 42 There is a higher frequency of depression among patients with cardiovascular diseases, 42 and depression might also represent a cardiovascular risk factor. 43, 44 Although antidepressants, such as SSRIs, are the first-line therapy for depression, clinical data on potential cardiovascular effects of SSRI treatment are inconclusive. [13] [14] [15] [16] [17] [18] [19] Here, we provide evidence that chronic intake of the SSRI fluoxetine promotes atherosclerotic plaque formation in a mouse model of atherosclerosis by enhancing integrin activity on circulating leukocytes.
Platelet 5-HT is involved in inflammatory diseases, such as obesity, 45 colitis, 46 or asthma. 47 Moreover, it was shown that 5-HT triggers immune cell activation leading to proinflammatory cytokine production. 46 Thus, the proatherogenic phenotype after fluoxetine treatment was surprising because we expected a more anti-inflammatory phenotype after platelet 5-HT depletion.
Arterial inflammation is caused by endothelial cell activation that promotes leukocyte recruitment, which is an initial step in atherogenesis. We found that fluoxetine increased vascular permeability and enhanced leukocyte recruitment by amplifying chemokine-induced activation of integrins on circulating monocytes and neutrophils. Conversely, blocking 5-HT synthesis with a pharmacological TPH1 inhibitor attenuated plaque formation in the initial lesion formation, an effect that was no longer present at the later stage of atherogenesis. Thus, fluoxetine mediates proatherogenic effects despite peripheral 5-HT depletion. We may speculate that after chronic fluoxetine intake, enhanced leukocyte recruitment because of integrin activation might override anti-inflammatory effects caused by depletion of peripheral 5-HT. In fact, although displaying enhanced in vivo leukocyte adhesion and plaque formation, fluoxetine-treated mice had significantly reduced CCL5 mRNA levels in aortas. Because we did not observe any modulation of endothelial adhesion molecules VCAM-1 and ICAM-1 by fluoxetine, we assume that the augmented vascular permeability could be a secondary consequence of fluoxetine-mediated leukocyte activation and arterial infiltration. However, we cannot exclude potential effects of fluoxetine on endothelial cell-cell junctions.
The transient decrease in circulating leukocytes (mainly granulocytes) and enhanced arterial adhesion are somewhat conflicting with previously published data. Duerschmied et al 9 reported that absence of peripheral 5-HT by genetic TPH1 deficiency or pharmacological depletion with fluoxetine in wild-type mice causes mild neutrophilia and a diminished neutrophil adhesion to postcapillary venules. In a subsequent study, the same group demonstrated that acute fluoxetine treatment transiently increases plasma 5-HT concentrations because of impaired uptake by platelets, thereby promoting leukocyte-endothelial interactions. 32 However, we showed that fluoxetine pretreatment caused a plaque phenotype similar to the one observed in our standard experimental setup, arguing against the possibility that transiently elevated 5-HT plasma levels provoke atherosclerosis outcome.
More likely, the opposing results might be explained by differences in the vascular bed (micro-versus macrovasculature) and the atherogenic background in our mouse model. Duerschmied et al 9 measured venular leukocyte recruitment in the microcirculation while we performed intravital microscopy of atherosclerosis-prone carotid arteries. Previous studies already highlighted dissimilarities in neutrophil adhesion between micro-and microvasculature. 22, 48 Site-specific differences in the mechanisms underlying leukocyte recruitment between the different vascular beds may account for this phenomenon. Moreover, the underlying hypercholesterolemia because of ApoE deficiency in combination with HFD leads to endothelial dysfunction in our atherosclerosis mouse model. 49 The relevance of the inflammatory setting is supported by the finding that wild-type mice treated with fluoxetine did not have the transient reductions in blood cell counts as observed in ApoE −/− mice. At inflammatory sites, leukocytes extravasate into the vessel wall through a series of events called leukocyte adhesion cascade. This process, consisting of leukocyte rolling on the endothelium, followed by adhesion and finally transendothelial migration, is predominately mediated by selectins and integrins. 50 Several studies showed that integrin activation and clustering are crucial in atherogenesis. 22, 48 Although we did not observe increased expression of adhesion molecules on circulating neutrophils, we found an enhanced CCL5-induced β1 and β2 integrin-binding activity on blood neutrophils as well as classical monocytes in fluoxetine-treated mice. Our data suggest that the effect of fluoxetine on integrin activation is only detectable in the presence of enhanced chemokine levels because it is the case during an inflammatory setting like chronic hypercholesterolemia. Solely fluoxetine but not 5-HT increased integrin activation on cells (murine and human), supporting the notion that the proatherogenic effects of fluoxetine are independent of its role in platelet 5-HT depletion. Our conclusion is further strengthened by the observation that pharmacological inhibition of the 5-HT synthesizing enzyme TPH1 did not aggravate atherosclerosis. Interestingly, TPH1 inhibition with LP533401 mitigated lesion formation after 2 weeks HFD, an effect no longer observed after 4 weeks. In fact, a previous study reported that platelet-specific JAM-A (junctional adhesion molecule A) deficiency only affected early lesion formation in aortic roots evidenced after 2 weeks of HFD but not at later stages. 51 We speculate that platelet reactivity, which might be particularly relevant at the onset of atherogenesis, is altered by TPH1 inhibition. LP533401 was previously described to reduce obesity by promoting brown adipose tissue thermogenesis. 21 Whether pharmacological blocking of TPH1 and thus reducing peripheral 5-HT may not only be effective in treating obesity and other related clinical disorders, such as type 2 diabetes mellitus, but also atherogenesis or atherothrombotic events deserves further investigations.
A limitation of our study is that we could not ultimately clarify how fluoxetine enhances integrin activation. In agreement with the literature, we detected 5-HTRs (ie, 5-HTR1b, 5-HTR2a) and SERT mRNA expression in murine monocytes and neutrophils. 52 Fluoxetine might affect integrin activity through signaling via binding either to SERT or to one of the 5-HTRs. In fact, a direct interaction between αIIbβ3 integrin and SERT in platelets has been reported to influence SERT activity. 53 The other explanation might be that fluoxetine interacts with one of the 5-HTRs expressed by myeloid cells and thereby affects integrin activation. In support of this possibility, affinity assays revealed binding of fluoxetine to different 5-HTRs. 37 Here, we were able to detect 5-HTR1b and 5-HTR2a mRNA expression in murine monocytes and neutrophils. The exact mechanism of integrin inside-out signaling is still incompletely understood. It is believed that G proteincoupled receptor stimulation, via phospholipase C and downstream activation of the small GTPase Rap1, mediates integrin conversion to the high-affinity conformation and thereby ICAM-1 and VCAM-1 binding. 41, 54, 55 However, we excluded the possibility that fluoxetine interacts with 5-HTR2a to stimulate an intracellular Ca 2+ response. Because 5-HT induced a strong intracellular Ca 2+ response via 5-HTR2a, the question arises why fluoxetine but not 5-HT enhanced integrin activity in vitro. Considering that the 2 detected 5-HTRs are coupled to different G proteins (5-HTR1b to G i and 5-HTR2a to G q ), 38 it is likely that fluoxetine-and 5-HT-mediated 5-HTR signaling responses might be different depending on which receptors are preferentially activated. In fact, fluoxetine binds to 5-HTR2a with a much higher affinity than to 5-HTR1b. 37 Because enhanced integrin-mediated binding was only observed on CCL5 costimulation, whereas fluoxetine alone did not promote integrin binding to VCAM-1 or ICAM-1, another possible explanation might be that fluoxetine directly acts on CCL5 chemokine receptors CCR1 and CCR5. It is also conceivable that fluoxetine prevents the inactivation of integrins, thereby prolonging integrin activity. Thus, the exact mechanism by which fluoxetine amplifies integrin activity remains to be clarified.
A crucial question that arises is whether the proatherogenic effect of fluoxetine is unique or possibly a common side effect of SSRIs in general. In support of the latter possibility, the effect of escitalopram, the newest approved SSRI, was comparable to fluoxetine-induced binding to VCAM-1. The effect on β2 integrins was less prominent. In support of a broader implication, a study with adult female cynomolgus macaques treated with the SSRI sertraline showed extended coronary artery atherosclerosis in treated primates. 56 Additional studies testing various SSRIs in common experimental models of atherosclerosis are needed to further address the proatherogenic effects of these drugs and the underlying mechanisms.
In conclusion, we provide the first experimental proof that the SSRI fluoxetine may promote atherosclerosis by amplifying CCL5-mediated integrin activation in a 5-HT-independent manner and therefore potentially enhances the risk for acute cardiovascular events, such as myocardial infarction. Given the increasing use of antidepressant drugs, potential proatherogenic effects of SSRIs in cardiovascular risk patients and incidence of acute cardiovascular events should be carefully monitored.
